Bellevue Life Sciences Acquisition, a biotech-focused SPAC formed by Bellevue Capital Management, priced its IPO of 6 million units at $10 each.
The units began listing today on the Nasdaq under the ticker symbol BLACU. Each consists of one share, a warrant and one right to receive one-tenth of a share upon completion of a merger.
After the securities begin separate trading, stock, warrants and rights are expected to be listed under the symbols BLAC, BLACW and BLACR, respectively. The offering is expected to close Feb. 14.
Bellevue registered the offering in May 2022.
CEO and Director Kuk Hyoun Hwang is the managing partner of BCM, which he founded in August 2012. BCM is the South Korea advisor for BAM, a subsidiary of Bellevue Group AG, a Swiss financial group holding company with global healthcare investing expertise which is publicly listed on the Swiss Exchange and oversees assets under management of approximately $11 billion
Chardan is sole book-running manager for the SPAC’s offering. Read more.
